Ranibizumab - CAS 347396-82-1

Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121, and VEGF165. Ranibizumab's ability to selectively target and neutralize VEGF-A isoforms has made it a crucial component of research and treatment strategies for wet wet age-related macular degeneration (AMD) .

VEGFR

Tyrosine Kinase/Adaptors, Angiogenesis

347313

0.9822

-20°C

Ice Packs

Inhibitory Antibodies